Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV)

56 filings reported holding ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q2 2024.
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 23.5M shares of 31.3M outstanding shares and own 74.91% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.34M shares), PERCEPTIVE ADVISORS LLC (5.36M shares), Sands Capital Ventures, LLC (2.12M shares), CITADEL ADVISORS LLC (2.12M shares), MARSHALL WACE, LLP (949K shares), WELLINGTON MANAGEMENT GROUP LLP (888K shares), BlackRock Inc. (767K shares), VANGUARD GROUP INC (746K shares), Paradigm Biocapital Advisors LP (660K shares), and GEODE CAPITAL MANAGEMENT, LLC (308K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.